Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter favorable biodistribution profile in non-human primates using a clinically validated editing strategy
You might also be interested in reading Bitcoin Skyrockets Past $61K—Over $23M in Shorts Wiped Out .